256 related articles for article (PubMed ID: 33257014)
1. Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement.
Gressel GM; Marcus JZ; Mullen MM; Sinno AK
Gynecol Oncol; 2021 Jan; 160(1):312-321. PubMed ID: 33257014
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulant (DOACs) prescribing practices of members of the Society of Gynecologic Oncology and American Society of Clinical Oncology.
Scanlon LR; Khaksari B; Goel S; Nevadunsky NS; Wright JD; Gressel GM
Gynecol Oncol; 2023 Jun; 173():68-73. PubMed ID: 37105059
[TBL] [Abstract][Full Text] [Related]
3. Defining practice patterns in gynecologic oncology to prevent pulmonary embolism and deep venous thrombosis.
Martino MA; Williamson E; Rajaram L; Lancaster JM; Hoffman MS; Maxwell GL; Clarke-Pearson DL
Gynecol Oncol; 2007 Sep; 106(3):439-45. PubMed ID: 17599396
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
5. Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice.
Rimel BJ; Burke WM; Higgins RV; Lee PS; Lutman CV; Parker L
Gynecol Oncol; 2015 May; 137(2):280-4. PubMed ID: 25735256
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban Used in the Treatment Patients With Gynecologic Cancer and Venous Thromboembolism: The Experience of Instituto Nacional de Câncer-Rio de Janeiro, Brazil.
Renni MJP; Araujo MLC; Trugilho I; Bergmann A; de Morais E Coura CP
Int J Gynecol Cancer; 2017 Jun; 27(5):1042-1045. PubMed ID: 28498242
[TBL] [Abstract][Full Text] [Related]
7. Validation of a venous thromboembolism risk assessment model in gynecologic oncology.
Stroud W; Whitworth JM; Miklic M; Schneider KE; Finan MA; Scalici J; Reed E; Bazzett-Matabele L; Straughn JM; Rocconi RP
Gynecol Oncol; 2014 Jul; 134(1):160-3. PubMed ID: 24796634
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants (DOACs) use for prolonged venous thromboembolism prophylaxis following surgery for gynaecological malignancies in Australia and New Zealand - A clinician survey.
Boo M; Simcock B; Sykes P; Brand A
Aust N Z J Obstet Gynaecol; 2024 Feb; 64(1):36-41. PubMed ID: 37434425
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants in patients with cancer.
Bossaer JB; Covert KL
Am J Health Syst Pharm; 2019 Jul; 76(14):1019-1027. PubMed ID: 31361880
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
11. Use of direct oral anticoagulants for postoperative venous thromboembolism prophylaxis after surgery for gynecologic malignancies.
Boo M; Sykes P; Simcock B
Int J Gynecol Cancer; 2022 Feb; 32(2):189-194. PubMed ID: 34992129
[TBL] [Abstract][Full Text] [Related]
12. Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer.
Soff GA
J Natl Compr Canc Netw; 2018 May; 16(5S):670-673. PubMed ID: 29784753
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
14. New anticoagulants in cancer patient treatments.
Arobelidze S; Haddad A; Spiro T; Daw H
Anticancer Drugs; 2016 Oct; 27(9):832-8. PubMed ID: 27387143
[TBL] [Abstract][Full Text] [Related]
15. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population.
Hedvat J; Howlett C; McCloskey J; Patel R
J Thromb Thrombolysis; 2018 Nov; 46(4):483-487. PubMed ID: 30191357
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions.
Riess H; Prandoni P; Harder S; Kreher S; Bauersachs R
Crit Rev Oncol Hematol; 2018 Dec; 132():169-179. PubMed ID: 30447923
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of direct oral anticoagulants following ultrasound-assisted catheter directed thrombolysis for venous thromboembolism.
Kelley D; Wright L; Ohman K; Ferreira J
J Thromb Thrombolysis; 2018 Jul; 46(1):58-61. PubMed ID: 29797208
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism prophylaxis for laparoscopic surgery: a survey of members of the Society of Gynecologic Oncology.
Worley MJ; Rauh-Hain JA; Sandberg EM; Muto MG
Int J Gynecol Cancer; 2013 Jan; 23(1):208-15. PubMed ID: 23221603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
